Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

Ajay K. Gopal, Robert Chen, Scott E. Smith, Stephen M. Ansell, Joseph D. Rosenblatt, Kerry J. Savage, Joseph M. Connors, Andreas Engert, Emily K. Larsen, Xuedong Chi, Eric L. Sievers, Anas Younes

Research output: Contribution to journalArticle

146 Scopus citations

Abstract

We present response and survival outcomes of a pivotal phase 2 trial of the antibody-drug conjugate brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant (N = 102) after a median observation period of approximately 3 years.Median overall survival and progression-free survival were estimated at 40.5months and 9.3months, respectively. Improved outcomes were observed in patients who achieved a complete remission (CR) on brentuximab vedotin, with estimated 3-year overall survival and progression-free survival rates of 73% (95% confidence interval [CI]: 57%, 88%) and 58%(95% CI: 41%, 76%), respectively, in this group (medians not reached).Of the 34 patients who obtained CR, 16 (47%) remain progression-free after a median of 53.3 months (range, 29.0 to 56.2 months) of observation; 12 patients remain progression-free without a consolidative allogeneic stem cell transplant. Younger age, good performance status, and lower disease burden at baseline were characteristic of patients who achieved a CR and were favorable prognostic factors for overall survival. These results suggest that a significant proportion of patients who respond to brentuximab vedotin can achieve prolonged disease control.

Original languageEnglish (US)
Pages (from-to)1236-1243
Number of pages8
JournalBlood
Volume125
Issue number8
DOIs
StatePublished - Feb 19 2015

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma'. Together they form a unique fingerprint.

  • Cite this

    Gopal, A. K., Chen, R., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Connors, J. M., Engert, A., Larsen, E. K., Chi, X., Sievers, E. L., & Younes, A. (2015). Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood, 125(8), 1236-1243. https://doi.org/10.1182/blood-2014-08-595801